Fig. 4. FX11 treatment significantly reduces ¹⁸F-FDG uptake in tumor with mutant TP53 status.

Subcutaneous PDXs including (A) wild type TP53 (JH024) and (B) mutant TP53 (JH015) were treated with vehicle or FX11 (2.2 mg/Kg) i.p. for seven consecutive days. On the day of imaging (D1 and D7), mice were injected with 250 μCi of [¹⁸F]-FDG via the tail vein and imaged 45 minutes post-injection. While FX11 treatment did not significantly reduce the tumor ¹⁸F-FDG uptake in mice bearing JH024 (A), the treatment significantly reduced the ¹⁸F-FDG in mice bearing JH015 (B). Arrowheads point towards tumor location on the mouse flank. Histograms shown at the bottom panels of figure represent the standard uptake values (SUV) in tumors. SUV in tumors were normalized by dividing the values with values of ¹⁸F-FDG update in the liver of each animal at the time of image acquisition. Points, mean ± SEM. N = 3–4 mice per group. *P=0.0446, compared to vehicle treated mice.